Related Experiment Videos
CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma.
Toyoki Yoshimoto1,2, Miwa Tanaka1, Mizuki Homme1
1Division of Carcinogenesis, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Cancer Research
|April 14, 2017
Summary
A new mouse model for CIC-DUX4 sarcoma (CDS) aids in identifying CCND2 and MUC5AC as biomarkers. This model also helps explore new therapeutic agents for this rare cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- CIC-DUX4 sarcoma (CDS) is a rare small round cell sarcoma.
- CDS shares morphological similarities with Ewing sarcoma (ES) but is a distinct disease entity.
- There is a need for specific biomarkers to differentiate CDS from ES.
Purpose of the Study:
- To develop an ex vivo mouse model for CDS.
- To identify reliable biomarkers for CDS diagnosis.
- To explore potential therapeutic strategies for CDS.
Main Methods:
- Generation of a mouse model by transducing embryonic mesenchymal cells (eMC) with CIC-DUX4 cDNA.
- Gene expression profiling of CDS and eMC.
- Immunohistochemistry (IHC) analysis for biomarker validation.
- In vitro gene silencing and drug sensitivity assays.
Main Results:
- The mouse model rapidly developed aggressive, undifferentiated sarcomas.
- Upregulation of downstream genes including PEA3 family, CCND2, CRH, and ZIC1 was observed in CDS.
- CCND2 and MUC5AC were identified as reliable IHC biomarkers distinguishing CDS from ES.
- Gene silencing of CIC-DUX4, CCND2, RET, and BCL2 inhibited tumor growth.
- Palbociclib and trabectedin demonstrated efficacy in blocking mouse CDS growth.
Conclusions:
- The developed mouse model is a valuable tool for studying CDS biology.
- CCND2 and MUC5AC serve as crucial biomarkers for CDS classification.
- The study provides a platform for discovering novel therapeutic agents for CDS.